ecrin-mdr-crcClinical2022Colorectal cancerCancer-Biliary tree (gall bladder and bile duct)Cancer-Bowel-AnalCancer-LiverCancer-PancreaticHepatobiliary cancerCancer-Bowel-Small bowel (duodenum and ileum)Cancer-Oesophageal (gullet)Oesophageal cancerPancreatic cancerCancer-Bowel-Back passage (rectum) or large bowel (colon)Cancer recurrenceGastric cancerCancer-StomachCancer-bowel-analCancer-bowel-small Bowel (duodenum And Ileum)Colorectal CancerHepatobiliary CancerCancer-oesophageal (gullet)Pancreatic CancerCancer RecurrenceCancer-liverCancer-biliary Tree (gall Bladder And Bile Duct)Cancer-pancreaticOesophageal CancerCancer-stomachGastric CancerCancer-bowel-back Passage (rectum) Or Large Bowel (colon)Observationalhttps://newmdr.ecrin.org/Study/2754854Australia8ECRIN MDRNot yet recruitingfalseTranexamic Acid and Cancer Recurrence after Gastrointestinal Cancer Surgery; A nested substudy of the Tranexamic Acid to Reduce Infection After Gastrointestinal Cancer Surgery (TRIGS) trialInterventions: This substudy nested within the multicentre, pragmatic, double-blind, randomised TRIGS trial NCT04192435. Assessment will be completed once at 5 years post operatively via cancer registry and the National Death Index (NDI will compare cancer-free survival in patients receiving tranexamic acid, or matched p)lacebo, for gastrointestinal cancer surgery. All adult patients scheduled for elective or semi-elective open or lap-assisted gastrointestinal cancer surgery (oesophageal, gastric, hepatobiliary, pancreatic, colorectal) with one or more risk factors for complications, will be included. Primary outcome(s): Cancer-free survival form state cancer registries[5 years from Gastrointestinal surgery] Study Design: Purpose: Natural history;Duration: Longitudinal;Selection: Defined population;Timing: Prospective2022-08-152754854ACTRN12622000995774